

Hans-Georg Wirsching

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/600325/publications.pdf>

Version: 2024-02-01

48
papers

2,908
citations

394421

19
h-index

265206

42
g-index

48
all docs

48
docs citations

48
times ranked

4544
citing authors

#	ARTICLE	IF	CITATIONS
1	DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. <i>Lancet Oncology</i> , The, 2017, 18, 682-694.	10.7	586
2	Advances in the molecular genetics of gliomas â€” implications for classification and therapy. <i>Nature Reviews Clinical Oncology</i> , 2017, 14, 434-452.	27.6	497
3	Glioblastoma. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2016, 134, 381-397.	1.8	289
4	<i>MGMT</i> Promoter Methylation Is a Strong Prognostic Biomarker for Benefit from Dose-Intensified Temozolomide Rechallenge in Progressive Glioblastoma: The DIRECTOR Trial. <i>Clinical Cancer Research</i> , 2015, 21, 2057-2064.	7.0	264
5	Complete resection of contrast-enhancing tumor volume is associated with improved survival in recurrent glioblastomaâ€”results from the DIRECTOR trial. <i>Neuro-Oncology</i> , 2016, 18, 549-556.	1.2	187
6	CDKN2A/B homozygous deletion is associated with early recurrence in meningiomas. <i>Acta Neuropathologica</i> , 2020, 140, 409-413.	7.7	116
7	Multidimensional scaling of diffuse gliomas: application to the 2016 World Health Organization classification system with prognostically relevant molecular subtype discovery. <i>Acta Neuropathologica Communications</i> , 2017, 5, 39.	5.2	110
8	Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence. <i>Acta Neuropathologica</i> , 2018, 135, 955-963.	7.7	109
9	Integrated Molecular-Morphologic Meningioma Classification: A Multicenter Retrospective Analysis, Retrospectively and Prospectively Validated. <i>Journal of Clinical Oncology</i> , 2021, 39, 3839-3852.	1.6	93
10	Mutational patterns and regulatory networks in epigenetic subgroups of meningioma. <i>Acta Neuropathologica</i> , 2019, 138, 295-308.	7.7	74
11	Bevacizumab plus hypofractionated radiotherapy versus radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. <i>Annals of Oncology</i> , 2018, 29, 1423-1430.	1.2	65
12	Predicting outcome of epilepsy after meningioma resection. <i>Neuro-Oncology</i> , 2016, 18, 1002-1010.	1.2	64
13	Thymosin beta 4 gene silencing decreases stemness and invasiveness in glioblastoma. <i>Brain</i> , 2014, 137, 433-448.	7.6	44
14	Increased <i>HOXA5</i> expression provides a selective advantage for gain of whole chromosome 7 in IDH wild-type glioblastoma. <i>Genes and Development</i> , 2018, 32, 512-523.	5.9	40
15	Antiâ€”PD-L1 antibody direct activation of macrophages contributes to a radiation-induced abscopal response in glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 639-651.	1.2	34
16	The Role of Molecular Diagnostics in the Management of Patients with Gliomas. <i>Current Treatment Options in Oncology</i> , 2016, 17, 51.	3.0	32
17	Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 1002-1010.	1.7	32
18	Copy number profiling across glioblastoma populations has implications for clinical trial design. <i>Neuro-Oncology</i> , 2018, 20, 1368-1373.	1.2	28

#	ARTICLE	IF	CITATIONS
19	Arming oHSV with ULBP3 drives abscopal immunity in lymphocyte-depleted glioblastoma. <i>JCI Insight</i> , 2019, 4, .	5.0	24
20	Plinabulin, an inhibitor of tubulin polymerization, targets KRAS signaling through disruption of endosomal recycling. <i>Biomedical Reports</i> , 2019, 10, 218-224.	2.0	19
21	MRI and 18FET-PET Predict Survival Benefit from Bevacizumab Plus Radiotherapy in Patients with Isocitrate Dehydrogenase Wild-type Glioblastoma: Results from the Randomized ARTE Trial. <i>Clinical Cancer Research</i> , 2021, 27, 179-188.	7.0	16
22	Does Neuronal Activity Promote Glioma Progression?. <i>Trends in Cancer</i> , 2020, 6, 1-3.	7.4	15
23	Radiomic Analysis to Predict Outcome in Recurrent Glioblastoma Based on Multi-Center MR Imaging From the Prospective DIRECTOR Trial. <i>Frontiers in Oncology</i> , 2021, 11, 636672.	2.8	15
24	Targeted Therapies and Immune Checkpoint Inhibitors in Primary CNS Lymphoma. <i>Cancers</i> , 2021, 13, 3073.	3.7	15
25	Survival of brain tumour patients with epilepsy. <i>Brain</i> , 2021, 144, 3322-3327.	7.6	14
26	Thymosin β 4 induces folding of the developing optic tectum in the chicken (<i>Gallus domesticus</i>). <i>Journal of Comparative Neurology</i> , 2012, 520, 1650-1662.	1.6	13
27	Computational modelling of perivascular-niche dynamics for the optimization of treatment schedules for glioblastoma. <i>Nature Biomedical Engineering</i> , 2021, 5, 346-359.	22.5	13
28	Chordoid meningiomas can be sub-stratified into prognostically distinct DNA methylation classes and are enriched for heterozygous deletions of chromosomal arm 2p. <i>Acta Neuropathologica</i> , 2018, 136, 975-978.	7.7	11
29	Socioeconomic burden and quality of life in meningioma patients. <i>Quality of Life Research</i> , 2020, 29, 1801-1808.	3.1	11
30	Post-operative cardiovascular complications and time to recurrence in meningioma patients treated with versus without pre-operative embolization: a retrospective cohort study of 741 patients. <i>Journal of Neuro-Oncology</i> , 2018, 140, 659-667.	2.9	10
31	The management of lomustine overdose in malignant glioma patients. <i>Neuro-Oncology Practice</i> , 2014, 1, 178-183.	1.6	9
32	Cooperation of oncolytic virotherapy with VEGF-neutralizing antibody treatment in IDH wildtype glioblastoma depends on MMP9. <i>Neuro-Oncology</i> , 2019, 21, 1607-1609.	1.2	9
33	A vasculature-centric approach to developing novel treatment options for glioblastoma. <i>Expert Opinion on Therapeutic Targets</i> , 2021, 25, 87-100.	3.4	9
34	Management of diffusely infiltrating glioma in the elderly. <i>Current Opinion in Oncology</i> , 2015, 27, 502-509.	2.4	8
35	Age-associated and therapy-induced alterations in the cellular microenvironment of experimental gliomas. <i>Oncotarget</i> , 2017, 8, 87124-87135.	1.8	8
36	Complete Resection of Contrast-Enhancing Tumor Volume is Associated With Improved Survival in Recurrent Glioblastoma Results From the DIRECTOR Trial. <i>Neurosurgery</i> , 2015, 62, 209.	1.1	6

#	ARTICLE	IF	CITATIONS
37	MGMT promoter methylation as a prognostic biomarker for benefit from dose-intensified temozolomide rechallenge in progressive glioblastoma: First results from the randomized phase II DIRECTOR trial.. Journal of Clinical Oncology, 2014, 32, 2015-2015.	1.6	6
38	Does extent of resection matter in recurrent glioblastoma? Lessons from the DIRECTOR trial.. Journal of Clinical Oncology, 2015, 33, 2041-2041.	1.6	4
39	Fitness-to-drive for glioblastoma patients. Swiss Medical Weekly, 2021, 151, w20501.	1.6	3
40	m6A Regulator Expression Segregates Meningiomas Into Biologically Distinct Subtypes. Frontiers in Oncology, 2021, 11, 760892.	2.8	3
41	Negative allosteric modulators of metabotropic glutamate receptor 3 target the stem-like phenotype of glioblastoma. Molecular Therapy - Oncolytics, 2021, 20, 166-174.	4.4	2
42	Increase in contrast-enhancing volume of irradiated meningiomas reflects tumor progression and not pseudoprogression. Neuro-Oncology, 2021, 23, 1612-1613.	1.2	1
43	PATH-51. DNA COPY NUMBER PROFILING ACROSS GLIOBLASTOMA POPULATIONS HAS IMPLICATIONS FOR CLINICAL TRIAL DESIGN. Neuro-Oncology, 2018, 20, vi169-vi170.	1.2	0
44	ACTR-16. PERIPHERAL BLOOD CD4+ MONONUCLEAR CELL FRACTIONS ARE ASSOCIATED WITH OVERALL SURVIVAL AT FIRST RECURRENCE OF IDH-WILDTYPE GLIOBLASTOMA AFTER STANDARD CHEMORADIOTHERAPY: SECONDARY ANALYSES OF THE PHASE II DIRECTOR TRIAL. Neuro-Oncology, 2018, 20, vi14-vi14.	1.2	0
45	MNGI-14. LOSS OF HISTONE H3K27me3 IDENTIFIES A SUBSET OF MENINGIOMAS WITH INCREASED RISK OF RECURRENCE. Neuro-Oncology, 2018, 20, vi151-vi151.	1.2	0
46	Effect of silencing thymosin beta 4 gene expression on stemness and invasiveness in glioblastoma.. Journal of Clinical Oncology, 2013, 31, 2081-2081.	1.6	0
47	PATH-39. INTEGRATED MOLECULAR-MORPHOLOGICAL MENINGIOMA CLASSIFICATION: A MULTICENTER RETROSPECTIVE ANALYSIS, RETRO- AND PROSPECTIVELY VALIDATED. Neuro-Oncology, 2021, 23, vi123-vi124.	1.2	0
48	NIMG-54. DIFFUSE TUMOR GROWTH PATTERN IS ASSOCIATED WITH WORSE OUTCOME ONLY IN IDH WILDTYPE BUT NOT IN IDH MUTANT GLIOMAS WHO II AND III. Neuro-Oncology, 2020, 22, ii160-ii160.	1.2	0